sulfinpyrazone has been researched along with Mitral Valve Stenosis in 2 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Mitral Valve Stenosis: Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| BAssan, MM | 1 |
| Steele, PP | 1 |
| Weily, HS | 1 |
| Davies, H | 1 |
| Genton, E | 1 |
2 other studies available for sulfinpyrazone and Mitral Valve Stenosis
| Article | Year |
|---|---|
Sulfinpyrazone, mitral stenosis and atrial fibrillation.
Topics: Atrial Fibrillation; Humans; Mitral Valve Stenosis; Sulfinpyrazone | 1981 |
Platelet survival in patients with rheumatic heart disease.
Topics: Adenosine Diphosphate; Aortic Valve Stenosis; Blood Platelets; Cell Survival; Chromium Radioisotopes | 1974 |